Seeking Alpha

Mast Therapeutics rallies on heart failure data

  • Mast Therapeutics (MSTX) is up 12% in early action.
  • The company says MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model.
  • The data collected suggest the treatment may be promising way to improve left ventricular ejection fraction and end-systolic volume.
  • The company intends to "provide an update on its plans for MST-188 in heart failure later in 2014." (PR)
Comments (1)
  • Andre LaPlume
    , contributor
    Comments (182) | Send Message
     
    In the headline it should be "heart failure". HEAT failure was a CLSN flashback, and not a pleasant one.
    6 Jan, 08:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|